What is Daré Bioscience?
Daré Bioscience is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of novel therapies for women's health. Its mission centers on identifying, developing, and bringing to market a diverse portfolio of differentiated treatments aimed at improving outcomes and convenience for women across key areas including contraception, vaginal health, sexual health, and fertility. The company's strategic focus on this underserved market positions it for significant growth and impact.
How much funding has Daré Bioscience raised?
Daré Bioscience has raised a total of $36.6M across 5 funding rounds:
Multiple Rounds
$22.1M
Other Financing Round
$12M
Grant
$2.5M
Share Placement (2020): $6.8M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Share Placement (2020): $15M supported by Lincoln Park Capital Fund , LLC
Other Financing Round (2023): $12M, investors not publicly disclosed
Grant (2024): $2.5M, investors not publicly disclosed
Key Investors in Daré Bioscience
Lincoln Park Capital Fund , LLC
Lincoln Park Capital Fund, LLC is a notable investment firm that has previously provided significant backing to companies, suggesting a focus on growth-stage financing and capital solutions.
PPP
Public-Private Partnership
What's next for Daré Bioscience?
With the recent injection of major enterprise-level funding, Daré Bioscience is poised to accelerate its clinical development programs and potentially expand its research and development initiatives. This strategic backing is likely to facilitate the progression of its lead product candidates through late-stage clinical trials and toward regulatory submission. The company's ability to attract substantial investment signals confidence in its scientific approach and its potential to address critical unmet needs in women's healthcare, paving the way for future commercialization and market penetration.
See full Daré Bioscience company page
